On August 22, 2024, Cascade Pharmaceuticals announced the official launch of a Phase I clinical trial for its THR-β agonist, CS060380.
The trial, titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Ascending Doses of CS060380 in Healthy Subjects and Participants with Elevated LDL-C", successfully held its kickoff meeting at Xuhui Central Hospital in Shanghai.
沪ICP备88888888号